Approaches to Understanding COVID‐19 and its Neurological Associations

Abstract

There is an accumulating volume of research into neurological manifestations of coronavirus disease 2019 (COVID‐19). However, inconsistent study designs, inadequate controls, poorly validated tests, and differing settings, interventions, and cultural norms weaken study quality and comparability, hence the understanding of the spectrum, burden, and pathophysiology of these complications. Therefore, a global COVID‐19 Neuro Research Coalition, together with the World Health Organization, has reviewed reports of COVID‐19 neurological complications and harmonized clinical measures for future research. This will facilitate well‐designed studies using precise, consistent case definitions of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and neurological complications, with standardized forms for pooled data analyses that nonspecialists can use, including those in low‐income settings. ANN NEUROL 2021;89:1059–1067

COVID-19 and mental health in children and adolescents: a diagnostic panel to map psycho-social consequences in the pandemic context

“…When considering the environmental factors that may affect the child or adolescent as a result of the pandemic (Fig. 4 ), it is of course important to consider if there have been infections in the local environment and if these have left consequences that have a psychological impact on the health of the caregivers or other important human [ 32 , 33 , 35 , 36 , 38 , 82 , 83 ].

Fig.

…”

Zentralnervöse Befunde bei COVID-19

“…Welle involviert ist, weiß auch, dass dies kaum realisierbar sein dürfte. Eine Kompromisslösung stellen Register dar, wie sie in vielen Ländern bereits angestoßen wurden [4]. Hieraus müssen weitere Erkenntnisse erwachsen, die vielleicht in Zeiten flacheren Wellengangs auch durch Studien untermauert werden können.…”

Short‐ and long‐term outcome and predictors in an international cohort of patients with neuro‐COVID‐19

“…The spectrum of coronavirus disease 2019 (COVID‐19) includes several neurological manifestations that, when present, are associated with higher severity and worse outcome [ 1 , 2 , 3 , 4 ]. However, neurological symptoms, signs and diagnoses in patients with COVID‐19 (neuro‐COVID) vary according to the target populations, setting (inpatients vs. outpatients), diagnostic criteria and the background of those in charge of data collection [ 5 ]. At present, there are only few publications with follow‐up, mainly from single centre studies [ 6 ] or non‐hospitalized patients [ 7 ], or based on self‐reports [ 8 ], electronic databases [ 9 , 10 ], small samples [ 11 ], or with short follow‐up [ 12 , 13 ] or high attrition rates [ 14 ].…”